FDA approves talazoparib with enzalutamide for earlier prostate cancer

Medical Tech

Published on:

Source: U.S. Food and Drug AdministrationBy: Center for Drug Evaluation and Research (CDER) · 26 OctoberDate: 10/26/2026, 12:00:00 AM
2026 On October 26, 2026, the Food and Drug Administration (FDA) approved talazoparib (Talzenna, Pfizer Inc.) in combination with enzalutamide for the treatment of adults with metastatic androgen pathway modulation-naïve or -sensitive (mAPMN/S) prostate cancer with homologous recombination repair (HRR)…
Continue reading with a subscription
This article is available to subscribers. Subscribe to read it in full, or sign in if you already have an account.
SubscribeSign in